Ramsay James, Shernan Stanton, Fitch Jane, Finnegan Paul, Todaro Thomas, Filloon Thomas, Nussmeier Nancy A
Department of Anesthesiology, Emory University Hospital, Atlanta, GA , USA.
J Thorac Cardiovasc Surg. 2005 Feb;129(2):300-6. doi: 10.1016/j.jtcvs.2004.06.005.
Recent consensus statements recommend cardiac enzyme release as the essential criterion for diagnosing myocardial infarction. However, the outcome implications of cardiac enzyme release in patients undergoing coronary artery bypass grafting are controversial.
Eight hundred patients were followed for 30 days after elective on-pump coronary artery bypass grafting in a multicenter, prospective, randomized trial of the anti-C5 complement antibody pexelizumab. Data from centralized electrocardiography and creatine kinase MB analyses were examined for any association with death or severe left ventricular dysfunction.
More than half of the 800 patients had peak creatine kinase MB levels of more than 5 times the upper limit of 5 ng/mL set by the core laboratory. The median peak value was 29 ng/mL. The incidence of the combined outcome (death or severe left ventricular dysfunction) was 1.7% if the peak creatine kinase MB level was less than 25 ng/mL and 18.0% if 100 ng/mL or greater (P < .01). Similarly, the incidence of new Q-wave myocardial infarction was 3.9% if the peak creatine kinase MB level was less than 25 ng/mL and 30.6% if 100 ng/mL or greater (P < .01). In a multivariate analysis that included preoperative and intraoperative factors, as well as peak enzyme release and Q-wave myocardial infarction, the strongest predictor of the combined outcome was a peak creatine kinase MB level of 100 ng/mL or greater. New Q-wave myocardial infarction did not significantly predict the combined outcome.
Increased postoperative peak creatine kinase MB level, especially when 20 times or more of the upper limit of normal, indicates increased risk of severe postoperative left ventricular dysfunction and mortality within 30 days of coronary artery bypass grafting. High peak enzyme level is a stronger predictor of adverse outcomes than is postoperative Q-wave myocardial infarction in this population.
近期的共识声明推荐将心肌酶释放作为诊断心肌梗死的基本标准。然而,冠状动脉旁路移植术患者心肌酶释放对预后的影响存在争议。
在一项关于抗C5补体抗体培昔利珠单抗的多中心、前瞻性、随机试验中,对800例患者在择期体外循环冠状动脉旁路移植术后进行了30天的随访。检查来自中央心电图和肌酸激酶MB分析的数据,以确定其与死亡或严重左心室功能障碍的任何关联。
800例患者中,超过一半的患者肌酸激酶MB峰值水平超过核心实验室设定的5 ng/mL上限的5倍。中位数峰值为29 ng/mL。如果肌酸激酶MB峰值水平低于25 ng/mL,联合结局(死亡或严重左心室功能障碍)的发生率为1.7%;如果峰值为100 ng/mL或更高,则发生率为18.0%(P <.01)。同样,如果肌酸激酶MB峰值水平低于25 ng/mL,新发Q波心肌梗死的发生率为3.9%;如果峰值为100 ng/mL或更高,则发生率为30.6%(P <.01)。在一项包括术前和术中因素以及酶释放峰值和Q波心肌梗死的多变量分析中,联合结局的最强预测因素是肌酸激酶MB峰值水平为100 ng/mL或更高。新发Q波心肌梗死对联合结局无显著预测作用。
术后肌酸激酶MB峰值水平升高,尤其是当超过正常上限20倍或更多时,表明冠状动脉旁路移植术后30天内发生严重左心室功能障碍和死亡的风险增加。在该人群中,酶峰值水平高比术后Q波心肌梗死更能预测不良结局。